title: Active immunotherapy with anti-idiotypic antibody for patients with nasopharyngeal carcinoma (NPC).
abstract: Two anti-idiotypic monoclonal antibodies (Ab2), designated 2H4 and 5D3, against two antitumor antibodies Ab1 (FC2 and HNL5) that recognize nasopharyngeal carcinoma (NPC) associated antigen were generated. They could substitute NPC antigen to induce humoral and cellular immune response against NPC cells in syngeneic mice. Nineteen patients with NPC at stage IV were chosen for active immunotherapy. They were treated with aluminum hydroxide-precipitated Ab2 2H4 or 5D3 accompanying radiotherapy. None of the immunization of anti-idiotypic monoclonal antibody (mAb) was associated with toxicity or allergies reactions. Nine patients with radiotherapy alone served as control. Both anti-anti-idiotypic antibodies (Ab3) and anti-NPC antibodies (Ab1') were increased and human anti-mouse Ig antibodies (HAMA) occurred in nineteen patients of the experimental group; whereas the levels of Ab1' did not rise in the control group. Serum IL-2, IFN-gamma, and TNF-alpha levels were increased in most patients in the experimental group, while in the control group, there were no differences of Ab1' and cytokine level between pretherapy and posttherapy. In addition, IL-2 mRNA expression in peripheral blood mononuclear cells (PBMC) of NPC patients was closely related to serum IL-2 (r = +0.8829) by in situ hybridization. Therefore, mouse anti-idiotypic antibodies 2H4 and 5D3 are safe for active immunotherapy and might enhance humoral and/or cellular immunity of NPC patients receiving radiotherapy.
authors.affiliation: Cancer Research Institute, Xiang-Ya School of Medicine, Central South University, Changsha 410078, Hunan, P.R. China.
authors.forename: Guancheng
authors.initials: G
authors.lastname: Li
authors.forename: Lu
authors.initials: L
authors.lastname: Xie
authors.forename: Guohua
authors.initials: G
authors.lastname: Zhou
authors.forename: Jiangao
authors.initials: J
authors.lastname: Zhu
authors.forename: Jinyue
authors.initials: J
authors.lastname: Hu
authors.forename: Qubing
authors.initials: Q
authors.lastname: Sun
mesh_terms: D000328:Adult; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000276:immunology / Q000628:therapy*; D014611:Vaccination
chemical_list: D000888:Antibodies, Anti-Idiotypic; D016207:Cytokines; D007106:Immune Sera